Abstract WMP9: Endovascular Thrombectomy Impact in the First Three “Golden” Hours
Background: Endovascular thrombectomy (EVT) substantially increases the likelihood of good outcome in acute ischemic strokes due to large vessel occlusion (LVO). Expediting EVT to achieve faster reperfusion is an important factor that correlates with good outcome. Ultra-early intervention in the first 3 “golden” hours from onset was not well characterized in recent trials.
Objective: We sought to assess the impact of early treatment within the first 3 hours on clinical outcomes in large, real life, world-wide practice.
Methods: We analyzed a multicenter international prospective cohort study of LVO patients treated with stent retriever thrombectomy (TREVO Registry) between11/2013 and 4/2016. We stratified patients based on treatment time, onset to groin puncture (GP), into 3 groups: 0-3, 3-6, >6 hrs. 90 day mRS was the primary outcome (0-2 good outcome). Logistic regression modeling was performed to evaluate the impact of treatment within the golden 3 hours on outcomes and to determine the independent factors associated with EVT initiation within 3 hours.
Results: In the 905 patients, GP occurred in: 23.1% 0-3 hrs, 44.3% 3-6 hrs and 32.6% >6 hrs. Table 1 shows similar baseline characteristics among the groups. Patient-level predictors of treatment within 3 hrs were age (aOR 1.1 per decade of age ≥18) and good ASPECTS (aOR 1.2 per point). No hospital-level predictors of early treatment were found. Patients treated within 3 hrs have a higher likelihood of good outcome as compared to those treated >3 hrs (aOR 2.0, 95% CI 1.4-2.9; p<0.001) after adjustment for age, NIHSS, IV tPA and mTICI ≥2b (Table 2). No differences were found in mortality and sICH. Treatment in the golden hours had the highest impact on excellent outcome rates (mRS 0-1) (Fig 1).
Conclusion: Early thrombectomy of LVO strokes, within the first three hours provides the highest impact compared with later time windows. Streamlining processes to deliver rapid intervention within 3 hours would improve clinical outcomes.
Author Disclosures: A. Sarraj: Research Grant; Significant; Stryker. Consultant/Advisory Board; Modest; Stryker. E. Veznedaroglu: Other Research Support; Significant; this registry supported by stryker. R.F. Budzik: None. J.D. English: Ownership Interest; Significant; Route 92 Medical. Consultant/Advisory Board; Modest; Silk Road Medical. Consultant/Advisory Board; Significant; Stryker, Medtronic. B.W. Baxter: Honoraria; Significant; Penumbra. Consultant/Advisory Board; Modest; Stryker, Medtronic. B.M. Bartolini: Consultant/Advisory Board; Modest; Stryker. A. Krajina: None. R.D. Shields: Employment; Significant; Stryker. R.G. Nogueira: Consultant/Advisory Board; Modest; Stryker Neurovascular (Trevo-2 Trial Principal Investigator- modest; DAWN Trial Principal Investigator- no compensation),, Medtronic (SWIFT Trial Steering Committee - modest; SWIFT-Prime Trial Steering Committee – no compensation; STAR Trial Angiographic Core Lab - significant), Penumbra (3D Separator Trial Executive Committee – no compensation), Editor-In-Chief Interventional Neurology Journal (no compensation). R. Gupta: Other Research Support; Modest; Zoll. Consultant/Advisory Board; Modest; Stryker, Medtronic. G.R. Spiegel: None. S.I. Savitz: None. L.D. McCullough: None. C.M. Farrell: None. D.S. Liebeskind: Research Grant; Significant; NIH. Consultant/Advisory Board; Significant; Medtronic, Stryker.
- © 2017 by American Heart Association, Inc.